Telix Pharmaceuticals (TLX) investor relations material

Executive summary

• Achieved Q2 2026 group revenue of US $247 million, up 7% quarter-over-quarter and 21% year-over-year, with Precision Medicine revenue up 9% QoQ and 30% YoY to US $202 million.

• U.S. FDA alignment reached for ProstACT Global Phase 3 study of TLX591-Tx in mCRPC, enabling progression to Part 2 in the U.S.

• Strategic collaboration with Regeneron initiated, focusing on next-generation radiopharmaceutical therapies, with an initial US $40 million non-refundable payment received.

• FY 2026 revenue and other income expected to exceed US $1 billion, tracking at the upper end of guidance.

Financial highlights

• Group revenue for Q2 2026 was US $247 million, up 21% year-over-year and 7% sequentially.

• Precision Medicine revenue reached US $202 million, up 30% YoY and 9% QoQ.

• TMS revenue was US $45 million, down 6% YoY but up 2% sequentially.

• Received US $40 million non-refundable payment from Regeneron.

Outlook and guidance

• FY 2026 revenue and other income expected to exceed US $1 billion, with revenue tracking at the upper end of US $950–970 million guidance plus US $40 million from Regeneron.

• FY 2026 R&D expenditure guidance updated to US $230–270 million, supporting accelerated clinical programs and strategic collaboration.